HNDG1MAG-36K | MILLIPLEX MAP Human Neurodegenerative Disease Magnetic Bead Panel 1 - Neuroscience Multiplex Assay

HNDG1MAG-36K
Design And Price Your Kit
Click To Print This Page

Overview

Replacement Information

Key Specifications Table

Analytes AvailableSpecies ReactivityKey ApplicationsDetection Methods
α2-Macroglobulin, Apo Al, Apo CIII, Apo E, Complement C3, Complement Factor H H Mplex Luminex xMAP
Description
Catalogue NumberHNDG1MAG-36K
Trade Name
  • MILLIPLEX
DescriptionMILLIPLEX MAP Human Neurodegenerative Disease Magnetic Bead Panel 1 - Neuroscience Multiplex Assay
OverviewThe MILLIPLEX® MAP Human Neurodegenerative Magnetic Bead Panel 1 (HNDG1MAG-36K) is to be used for the simultaneous quantification of the following 7 analytes in any combination: α-2-Macroglobulin, Apo A1, Apo CIII, Apo E, Complement C3 and Complement Factor H. This kit may be used for the analysis of all above analytes in human serum, plasma, and cerebrospinal fluid samples.

References:
Acta Neuropathol Commun. 2016 Feb 17;4:14. doi: 10.1186/s40478-016-0277-8.
CSF complement 3 and factor H are staging biomarkers in Alzheimer's disease.
Hu WT, Watts KD, Tailor P, Nguyen TP, Howell JC, Lee RC, Seyfried NT, Gearing M, Hales CM, Levey AI, Lah JJ, Lee EK; Alzheimer’s Disease Neuro-Imaging Initiative.
Background InformationNeurodegenerative disease is a condition characterized by the deterioration of neurons or their myelin sheath over time in the brain and/or spinal cord. These neurons are responsible for such everyday activities as processing sensory information, making decisions, and controlling movement. Because these cells are not easily regenerated, excessive cumulative damage can lead to age-related diseases such as Alzheimer's and Parkinson's disease, as well as other conditions such as amyotrophic lateral sclerosis (ALS) and epilepsy. These disorders are devastating and expensive, both on a personal and global level, and as population demographics continue to change, a therapeutic solution is critical. Consequently, research is underway to identify biomarkers that will help scientists not only understand the pathogenesis of neurodegenerative disease, but also identify people with these disorders before the onset of symptoms and potentially provide new therapeutic tools.
References
Product Information
Detection methodLuminex xMAP
ConfigurationDesign your multiplex kit by choosing available analytes within this panel.
Precision, %
  • Intra-assay:< 10
  • Inter-assay:
    α2-Macroglobulin & Complement C3 < 10
    All other analytes < 20
Panel TypeMAGNETIC Neuroscience
Applications
ApplicationThe analytes available for this multiplex kit are: α2-Macroglobulin, Apo Al, Apo CIII, Apo E, Complement C3 and Complement Factor H.
Key Applications
  • Multiplexing
Application Notes• This is a 2-hour incubation assay.
• This assay requires 25 μL of 1:40,000 diluted serum/plasma or 1:400 diluted CSF per well.
Biological Information
Species Reactivity
  • Human
Analytes Available
  • α2-Macroglobulin
  • Apo Al
  • Apo CIII
  • Apo E
  • Complement C3
  • Complement Factor H
Assay PanelEverything you need in a single kit.
Cross ReactivityCross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.
Accuracy
  • α2-Macroglobulin 104%
  • Apo AI 102%
  • Apo CIII 105%
  • Apo E 110%
  • Complement C3 75%
  • Complement Factor H 105%
Physicochemical Information
Sensitivity
  • See protocol for sensitivities of individual analytes
Standard Curve Range
  • Apo CIII: 0.01 – 40 ng/mL
  • Apo E, Complement C3: 0.05 – 200 ng/mL
  • Complement Factor H: 0.3 – 1,000 ng/mL
  • α-2-Macroglobulin: 0.5 – 2,000 ng/mL
  • Apo A1: 0.7 – 3,000 ng/mL
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsRecommended storage for kit components is 2 - 8°C.
Packaging Information
Material Size96-well plate
Transport Information
Supplemental Information
Specifications

Documentation

Protocols

Title
Protocol: Human Neurodegenerative Disease Magnetic Bead Panel 1

SDS

Title

Safety Data Sheet (SDS) 

References

Reference overviewPub Med ID
Plasma proteins predict conversion to dementia from prodromal disease.
Hye A, Riddoch-Contreras J, Baird AL, Ashton NJ, Bazenet C, Leung R, Westman E, Simmons A, Dobson R, Sattlecker M, Lupton M, Lunnon K, Keohane A, Ward M, Pike I, Zucht HD, Pepin D, Zheng W, Tunnicliffe A, Richardson J, Gauthier S, Soininen H, K³oszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S.
Alzheimers Dement. 2014 Nov;10(6):799- 807.e2  2014

25012867 25012867
Cerebrospinal fluid complement activation in patients with pneumococcal and meningococcal meningitis.
Mook-Kanamori, BB; Brouwer, MC; Geldhoff, M; Ende, Av; van de Beek, D
The Journal of infection  68  542-7  2014

Show Abstract
24412248 24412248

Brochure

Title
A closer look at immunoassay platforms. Beyond fit for purpse. Bring your biomarkers to life with EMD Millipore Immunoassay Platform Solutions.
Protein Detection Platform and Services Brochure
The Power of Biomarker Analysis

Technical Info

Title
96 well Template 2 Up
96 well Template Single
Quality Control Range: Human Neurodegenerative Disease Panel 1 Kit

Data Sheet

Title
Full Service Custom-built Assays

Posters

Title
MILLIPLEX MAP: Exercise, Signaling, and Your Brain (EMD)
Inflammation in Neurodegenerative Diseases
Multiplex Assays of Fifteen Human Complement Factors
Toxicology in drug discovery and development: Biomarkers and model organisms (EMD)